Avacta Group plc (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | Avacta Group plc | |||
| Name of scheme: | EMI scheme | |||
| Period of return: | From: | 28 April 2024 | 27 October 2024 | |
| Balance of unallotted securities under scheme(s) from previous return: | 803,006 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 527,626 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 275,380 | |||
| Name of applicant: | Avacta Group plc | |||
| Name of scheme: | LTIP scheme | |||
| Period of return: | From: | 28 April 2024 | 27 October 2024 | |
| Balance of unallotted securities under scheme(s): | 9,719,257 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 3,806,000 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 5,913,257 | |||
| Name of contact: | James Heseltine, Company Secretary |
| Telephone number of contact: | + 44 (0) 1904 217070 |